Zelluna–SEVERAL: grant, 202006 public grants + equity financing tog totalling €7.5m

	Period	2020-06-11
	Money taker	Zelluna Immunotherapy AS
	Money source	SEVERAL
	Product	private equity
	Index term	Zelluna–SEVERAL: investment, 202006 equity financing tog with public grants totalling €7.5m

Zelluna Immunotherapy AS. (6/11/20). "Press Release: Zelluna Immunotherapy Raises Funds to Fully Focus on Developing Allogeneic “Off-the-Shelf” TCR based Natural Killer (TCR-NK) Cell Therapies". Oslo.

Zelluna Immunotherapy, a T Cell Receptor (TCR) cell therapy company, today announces the completion of a fundraise to fully focus on the development of its proprietary TCR guided Natural Killer (NK) cell therapy platform (TCR-NK) for the treatment of cancers.

A total of approximately EUR 7.5 million has been raised in equity financing and public grants. Zelluna’s strategy is to concentrate on the development of TCR-NK cell therapy products based on its proprietary technology platform, where TCRs are functionally expressed in NK cells. The combination of the broad target range of TCRs with the inherent anti-tumor activity and allogeneic nature of NK cells could offer novel, safe, and effective “off the shelf” cell therapy treatments for solid cancer patients.

In support of this strategy, Zelluna has recently announced the formation of partnerships with world-renowned NK organizations, providing access to NK cells, manufacturing facilities and additional competency and expertise.

“Zelluna has taken an important step in fully focusing on pioneering TCR-NK products for the treatment of solid cancer patients. This funding will enable us to develop both Zelluna’s allogenic TCR-NK platform and novel TCR-NK products. The potential benefits of allogeneic products in manufacturing, scalability and immediate patient treatment have been recognized across the industry for some time,” said Namir Hassan, CEO, Zelluna Immunotherapy. “More recently, clinical data for CAR-NKs and TCR-Ts demonstrate the effectiveness of NK cells as “off-the-shelf” treatments and TCRs as successful solid tumor targeting mechanisms. Zelluna believes that its proprietary platform, combining TCRs with NKs may provide effective “off-the-shelf” treatment options for solid tumor patients. Working closely with world-class NK groups and organizations places Zelluna in a strong position to realize the potential of this novel treatment option for cancer patients.”

Zelluna aims to develop a number of allogeneic TCR-NK products for the treatment of solid cancers. Zelluna will secure new TCR targets through both internal development programs and in partnerships with other companies and groups.

About Zelluna Immunotherapy

Zelluna Immunotherapy is a company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more information, please visit www.zelluna.com

Contact Information:

Image Box PR
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency